allergy banner

Videos


Articles


Mast cell chymase suppresses functional parameters in primary human airway smooth muscle cells

Zhao, X.O., Melo, F.R., Sommerhoff, C.P., Paivandy, A. and Pejler, G. Allergy. First published: 26 February 2024

Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis

Wang N, Song J, Sun S-R, et al. Allergy. First published: 25 February 2024

Impact of air pollutants and meteorological factors on allergic rhinitis outpatient visits in Shanghai, China

Na, S., Yanan, H., Lufang, T., et al. Allergy. First published: 25 February 2024

Insights in intestinal immune tolerance: The role of the cleavage form of gasdermin D

Rossi, F., Votto, M. and Castagnoli, R. Allergy. First published: 25 February 2024

Mouse eosinophil-associated ribonuclease-2 exacerbates the allergic response

Nguyen, L.M., Kanda, A., Kamioka, Y., et al. Allergy. First published: 23 February 2024

Systematic review of the association between short chain fatty acids and allergic diseases

Sasaki M, Suaini NHA, Afghani J, et al. Allergy. First published: 23 February 2024

Epidermal barrier impairment predisposes for excessive growth of the allergy-associated yeast >Malassezia on murine skin

Ruchti F, Zwicky P, Becher B, Dubrac S, LeibundGut-Landmann S. Allergy. First published: 22 February 2024

Identification of fructose-bisphosphate aldolase as new pollen allergens

Song, L.-B., Zhang, L., Zhu, Y., et al. Allergy. First published: 20 February 2024

Artemisia annua sublingual immunotherapy in children with seasonal allergic rhinitis

Tang, L., Wang, P., Yang, X., et al. Allergy. First published: 20 February 2024

Airway epithelial cell cilia transcriptomic dysregulation is associated with the inflammatory phenotype in asthma

Devilliers, M.A., Brisebarre, A., Petit, et al. Allergy. First published: 19 February 2024

Global associations of macronutrient supply and asthma disease burden

Ni, D., Senior, A.M., Raubenheimer, D., Simpson, S.J., Macia, L. and Nanan, R. Allergy. First published: 19 February 2024

Pre-existing inflammation reduces the response to contact allergens in Tmem79-deficient mice

Jee, M.H., Funch, A.B., Weber, J.F., et al. Allergy. First published: 17 February 2024

Drug hypersensitivity: Past, present and future

Torres, M.J. and Doña, I. Allergy. First published: 16 February 2024

Colostrum is required for the postnatal ontogeny of small intestine innate lymphoid type 2 cells and successful anti-helminth defences

Rekima, A., van den Elsen, L., Isnard, C., et al. Allergy. First published: 13 February 2024

Is there a direct link between skin barrier dysfunction and asthma?

Santos, A.F. Allergy. First published: 13 February 2024

Response to correspondence: Prediction of adult asthma risk in early childhood using novel adult asthma predictive risk scores

Farhan, A.J., Kothalawala, D.M., Kurukulaaratchy, R.J., et al. Allergy. First published: 08 February 2024

Correspondence to “Oral immunotherapy in alpha-gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management?”

Chen, Y.-C., Lin, Y.-H., Lu, C.-T., Yii, C.-Y., Chen, P.-C. and Yong, S.-B. Allergy. First published: 13 February 2024

Identification of allergens from Aspergillus fumigatus—Potential association with lung damage in asthma

Rick E-M, Woolnough K, Richardson M, et al. Allergy. First published: 09 February 2024

Transitional care of adolescents and young adults with asthma and allergy—The healthcare professional perspective

Ödling, M., Lagercrantz, B., Goksör, E., et al. Allergy. First published: 09 February 2024

Immunotherapeutic effects of specific and nonspecific mRNA-lipid nanoparticles in a mouse model of HDM-induced airway inflammation

Thanasarnthungcharoen, C., Chanasit, S., Fievez, L., et al. Allergy. First published: 08 February 2024

Dupilumab-associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation

Thormann K, Lüthi A-S, Deniau F, et al. Allergy. First published: 05 February 2024

The skin microbiome in pediatric atopic dermatitis and food allergy

Tham EH, Chia M, Riggioni C, Nagarajan N, Common JEA, Kong HH. Allergy. First published: 03 February 2024

T-cell immune profile in blood of systemic mastocytosis: Association with disease features

Pérez-Pons A, Teodosio C, Jara-Acevedo M, et al. Allergy. First published: 01 February 2024

Citations: 138

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766

Citations: 98

The role of peripheral blood eosinophil counts in COVID-19 patients

Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482

Citations: 70

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639

Citations: 68

COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676

Citations: 65

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI-ARIA Position Paper

Klimek, L., Jutel, M., Akdis, C.A., Bousquet, J., Akdis, M., Torres, M.J., et al. Allergy. 2021; 76: 1624-1628

Citations: 61

Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?

Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618

Citations: 58

Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation

Klimek, L., Novak, N., Cabanillas, B., Jutel, M., Bousquet, J. and Akdis, C.A. Allergy. 2021; 76: 3307-3313

Citations: 55

Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives

Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M., et al. Allergy. 2021; 76: 1640-1660

Citations: 49

EAACI guidelines: Anaphylaxis (2021 update)

Muraro, A, Worm, M, Alviani, C, Cardona, V, DunnGalvin, A, Garvey, L, H, et al et al. Allergy. 2022; 2022; 77: 357– 377

Citations: 43

The role of allergen-specific IgE, IgG and IgA in allergic disease

Shamji, MH, Valenta, R, Jardetzky, T, Verhasselt, V, Durham, S, R, Würtzen, P, A, et al. Allergy. 2021; 76: 3627– 3641

Citations: 43

Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort

Papadopoulos, N.G., Mathioudakis, A.G., Custovic, A., Deschildre, A., Phipatanakul, W., Wong, G., et al. Allergy. 2021; 76: 1765-1775

Citations: 43

Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice

Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432

Citations: 42

Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353

Citations: 39

In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion

Augusto, G, Mohsen, MO, Zinkhan, S, Liu, X, Vogel, M, Bachmann, MF. Allergy. 2022; 77: 111– 117

Citations: 38

Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!

Krantz, M.S., Bruusgaard-Mouritsen, M.A., Koo, G., Phillips, E.J., Stone, C.A., Jr and Garvey, L.H. Allergy. 2021; 76: 2916-2920

Citations: 37

Elastase and exacerbation of neutrophil innate immunity are involved in multi-visceral manifestations of COVID-19

Guéant, J.-L., Guéant-Rodriguez, R.-M., Fromonot, J., Oussalah, A., Louis, H., Chery, C., et al. Allergy. 2021; 76: 1846-1858

Citations: 35

Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19

Adamo, S., Chevrier, S., Cervia, C., Zurbuchen, Y., Raeber, M.E., Yang, L., et al. Allergy. 2021; 76: 2866-2881

Citations: 34

Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity

Torres, MJ, Trautmann, A, Böhm, I, Scherer, K, Barbaud, A, Bavbek, S, et al. Allergy. 2021; 76: 1325– 1339

Citations: 34

The ingenious mast cell: Contemporary insights into mast cell behavior and function

Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 77: 83-99

Citations: 34

Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation

Khaitov, M., Nikonova, A., Shilovskiy, I., Kozhikhova, K., Kofiadi, I., Vishnyakova, L., et al. Allergy. 2021; 76: 2840-2854

Citations: 34

Interleukin-31: The “itchy” cytokine in inflammation and therapy

Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997

Citations: 32

Predictors of treatment response in chronic spontaneous urticaria

Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981

Citations: 31

Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing

Bianchi, L., Biondi, F., Hansel, K., Murgia, N., Tramontana, M. and Stingeni, L. Allergy. 2021; 76: 2605-2607

Citations: 31

Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I

Sokolowska, M, Rovati, GE, Diamant, Z, et al. Allergy. 2021; 76: 114– 130

Citations: 30

Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease

Celebi Sozener, Z, Ozdel Ozturk, B, Cerci, P, et al. Allergy. 2022; 77: 1418– 1449

Citations: 30

Advances and highlights in asthma in 2021

Agache, I, Eguiluz-Gracia, I, Cojanu, C, et al. Allergy. 2021; 76: 3390– 3407

The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414

Risk factors for severe and critically ill COVID-19 patients: A review

Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455

Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives

Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581

EAACI guidelines: Anaphylaxis (2021 update)

Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377

Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741

Advances and recent developments in asthma in 2020

Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146

The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update

Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022

A compendium answering 150 questions on COVID-19 and SARS-CoV-2

Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541

Management of anaphylaxis due to COVID-19 vaccines in the elderly

Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964

Predictors of treatment response in chronic spontaneous urticaria

Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981

Interleukin-31: The “itchy” cytokine in inflammation and therapy

Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997

Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review

Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016

Eczema herpeticum in atopic dermatitis

Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027

Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study

Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052

Direct assessment of individual skin barrier components by electrical impedance spectroscopy

Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106

Prenatal paraben exposure and atopic dermatitis-related outcomes among children

Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132

Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis

Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154

Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy

Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193

Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine

Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196

Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma

Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202

Identification of Ulocladium chartarum as an important indoor allergen source

Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206

Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis

Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214

Legends of allergy and immunology: Sergio Bonini

Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229

Medical algorithm: Peri-operative management of mastocytosis patients

Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235

Open Access Agreements with Wiley



Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley

Free access

18th World Immune Regulation Meeting



As ever, immune regulation is the hottest issue in basic and clinical sciences. With an outstanding list of speakers in this field, WIRM will be one of the key scientific event of the year 2024, being big enough to learn from other disciplines and small enough to personally meet the experts. Check out the website for more information by clicking here.
WIRM

Junior Members Corner



Dear Junior Members,

The International Severe Asthma forum (ISAF) was held in a hybrid format from 5-7 October 2023 in the beautiful city of Rome (Italy). The meeting was a great success, with senior experts and juniors learning together about the most relevant scientific advances in the field of asthma research, which can be translated into clinical practice. The organising committee, which the participation of the secretary of the Junior Member Assembly (JMA), Mattia Giovannini, carefully designed a comprehensive scientific programme divided into different plenary, symposium and keynote sessions, useful practical courses, and different poster sessions, where the most exciting data were presented, and vibrant discussions took place.


Moreover, the Pediatric Allergy and Asthma Meeting (PAAM) 2023 was held in Porto, Portugal, from 2 to 4 November 2023. Junior Members (JMs) from different countries were able to attend sessions that highlight the latest scientific information regarding drug allergy in children, chronic urticaria in childhood, the management of immunodeficiencies, when the hydrolysed formula is recommended, mastocytosis and how to prevent food allergy among others. This event has also facilitated in person networking with the experts. Besides, JMs have coordinated the Clinical Village, divided into different stations depending on the topic. The latest algorithms were posted, and attendees were able to interact with JM and discuss hot topics.

Best wishes,
The Junior Member Assembly


See more in the JM archive

EAACI Patients Organisation Committee Corner




The POC Reunion in the Annual Congress 2023



The POC has been participating in the EAACI Annual Congresses and focused meetings such as FAAM and PAAM since 2011. When Covid-19 pandemic and strict public health measures started in 2020, POC members continued attending the EAACI events virtually. For the first time in a long while, the POC returned to in-person participation in the Annual Congress Hamburg 2023.

Fifteen members of the committee attended the Annual Congress 2023 in-person. The special session ESS1 which was completely organised by the POC took place on the first day of the Congress with great success. Session was designed to discuss the “Benefits of engaging with patients in clinical trials and decision-making” with different stakeholders.

Giulia Gabrielli from European Medicine Agency (EMA) shared the framework for engagement between the Agency and the patients. Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, shared their experience in receiving the federal funding for allergy prevention and management in collaboration with the POC member Allergy & Anaphylaxis Australia. Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) presented their long-lasting track record in participation to research projects. POC Member Mikaela Odemyr, President of Asthma and Allergy Association Sweden shared her experience as a patient representative in participating the research design and planning process.

The session chairs were Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session also had a panel discussion where chairs invited the audience to share their experiences and best practises.

Additionally, POC members Sabine Schnadt (DAAB-Germany) presented “Managing the risk of patients with peanut allergy: the value of thresholds of reaction” in the industry session, Patricia Carmelo and Carolina Olivares (Fundacion Creciendo con Alergias Alimenarias-Chile) had two poster presentations; “Food Allergens that trigger anaphylaxis in children in Chile” and “Adrenaline Auto-injector in Chile, National Survey 2020”.

Several POC members attended the Beat Allergy Run & Walk on the 10th of June. The event was organised to contribute on providing much-needed aid as the collected funds were sent to those affected by the earthquakes in Turkey.

The POC believes the conferences and in-person meetings are useful in staying up to date with new developments in medicine, dissemination of knowledge, enabling interaction with opinion leaders, networking, developing consensus, and adoption of newer ideas relevant to the patient community. Going forward, committee members consider hybrid conventions a decent opportunity to increase accessibility and inclusivity. In 2024, POC is planning to attend the Annual Congress in Valencia and FAAM in Athens.